OMER News and Press, Omeros Corporation From 08/09/21

Omeros (NASDAQ:OMER): Q2 GAAP EPS of -$0.46 beats by $0.09. Revenue of $28.8M (+112.9% Y/Y) beats by $4.53M. At June 30, 2021, Omeros had cash, cash equivalents and short-term investments available for operations of $73.7 million. Press Release For further details see: Omeros EPS beats ...

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicat...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eas...

Omeros has had its PDUFA delayed by three months. The reason is that the FDA needs additional time to review data it had asked for. This represents a buying opportunity. For further details see: Omeros: PDUFA Delay Presents An Opportunity

AYDINOZON/iStock via Getty Images Bank of America has listed CRISPR Therapeutics ([[CRSP]] -0.7%), Omeros Corporation ([[OMER]] -4.4%), Kiniksa Pharma ([[KNSA]] -2.4%), and PMV Pharma ([[PMVP]] -0.6%) as actionable small and mid-cap biopharma companies with key updates in H2 2021.The analysts...

Omeros Corporation (OMER) released the results on organ function improvement for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).Narsoplimab, (OMS721) is an investigational human monoclonal antibody targeting an enzyme c...

-- Data on Organ Function Improvement Presented by Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering -- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment o...

-- Inhibitors of PDE7 Enzymes Could Treat Nicotine Abuse -- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan ind...

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesd...

Omeros (OMER) announces preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906.The trial is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics ((PK)) and pharmacodynamics ((PD)) of intravenous ...